Chemistry:Ilunocitinib
Ilunocitinib, sold under the brand name Zenrelia, is a veterinary medication used for the treatment of pruritus (itching) in dogs.[1][2] It is a non-selective janus kinase inhibitor.[2]
Ilunocitinib was approved for medical use in the United States in September 2024,[3] and in Canada in December 2024.[1]
Medical uses
Ilunocitinib is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least twelve months of age.[1][2][4]
Contraindications
It is not safe to administer vaccines to dogs that are concurrently receiving ilunocitinib.[4]
Society and culture
Legal status
Ilunocitinib was approved for medical use in the United States in September 2024,[5] and in Canada in December 2024.[1]
In June 2025, the Committee for Veterinary Medicinal Products of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Zenrelia, film-coated tablets, intended for dogs.[6] The applicant for this veterinary medicinal product is Elanco GmbH.[6]
Names
Ilunocitinib is the international nonproprietary name.[7]
Ilunocitinib is sold under the brand name Zenrelia.[1][2]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Cite error: Invalid
<ref>tag; no text was provided for refs namedCA PDL additions - ↑ 2.0 2.1 2.2 2.3 Cite error: Invalid
<ref>tag; no text was provided for refs namedZenrelia FOI summary - ↑ "FDA Approves New Treatment for Allergic Skin Conditions in Dogs". 19 September 2024. https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-new-treatment-allergic-skin-conditions-dogs.
This article incorporates text from this source, which is in the public domain.
- ↑ 4.0 4.1 "Dear Veterinarian Letter regarding important safety information associated with the use of Zenrelia (ilunocitinib tablets) for controlling pruritus associated with allergic dermatitis and atopic dermatitis in dogs". 1 October 2024. https://www.fda.gov/animal-veterinary/product-safety-information/dear-veterinarian-letter-regarding-important-safety-information-associated-use-zenrelia-ilunocitinib. This article incorporates text from this source, which is in the public domain.
- ↑ "Recent Animal Drug Approvals". 1 October 2024. https://www.fda.gov/animal-veterinary/approved-animal-drug-products-green-book/recent-animal-drug-approvals.
- ↑ 6.0 6.1 "Zenrelia EPAR". 13 June 2025. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/zenrelia. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 87". WHO Drug Information 36 (1). 2022.
 |  |
